From January 1, 1997, Pfizer's US pharmaceuticals group and its international pharmaceuticals group will be managed as a single global business to form the Pfizer Pharmaceuticals group.
The new organization will be headed by Henry McKinnell, vice president of Pfizer Inc (see page 28). Dr McKinnell said: "the new Pfizer Pharmaceuticals group will...enhance our global effectiveness while maintaining the unwavering concentration of individual country operations in their markets. I believe our leadership in these areas will allow us to achieve our goal of making Pfizer the world's premier, research-based health care company."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze